Frequency and management of troponin i elevation in patients treated with molecular targeted therapies in phase i trials

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 611-615

  Ederhy, Stephane ^a,b   Massard, Christophe ^c   Dufaitre, Ghislaine ^a,b   Balheda, Ratio ^c   Meuleman, Catherine ^a,b   Rocca, Carlos Gomez ^c   Izzedine, Hassane ^b,d   Cohen, Ariel ^a,b   Soria, Jean Charles ^c  

^a Saint Antoine University and Medical School   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cancer; Cardiotoxicity; Molecular targeted therapies; Troponin I elevation

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENZYME INHIBITOR; GADOLINIUM; KINESIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TROPONIN I; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; KINESIN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ASYMPTOMATIC DISEASE; BREAST CANCER; CANCER PATIENT; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTRAST ENHANCEMENT; DRUG RECHALLENGE; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LUNG TUMOR; MALE; METASTASIS; MOLECULARLY TARGETED THERAPY; MYOCARDITIS; PANCREAS TUMOR; PATHOPHYSIOLOGY; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; SOLID TUMOR; T WAVE INVERSION; THORAX PAIN; TRANSTHORACIC ECHOCARDIOGRAPHY; UROGENITAL TRACT TUMOR; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ANTAGONISM; ENZYMOLOGY; FRANCE; HEART FUNCTION TEST; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY; PREDICTIVE VALUE; TIME; TREATMENT OUTCOME; UPREGULATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; ENZYME INHIBITORS; FEMALE; HEART DISEASES; HEART FUNCTION TESTS; HUMANS; KINESIN; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS; PARIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME; TROPONIN I; UP-REGULATION;

EID: 84862247660     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9546-8     Document Type: Article

References (19)

1. Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187
2. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-591
3. Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332-344
4. Khakoo AY, Yeh ET (2008) Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol 5:655-667
5. Daher IN, Yeh ET (2008) Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med 5:797-805
6. Chu TF, Rupnick MA, Kerkela R et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-2019
7. Kerkelä R, Grazette L, Yacobi R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908-916
8. Khakoo AY, Kassiotis CM, Tannir N et al (2008) Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 112:2500-2508
9. Escudier B, Eisen T, Stadler WM, TARGET Study Group et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
10. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
11. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672
12. Romond EH, Perez EA, Bryant J et al (2000) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
13. Schmidinger M, Zielinski CC, Vogl UM et al (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204-5212
14. Cardinale D, Sandri MT, Colombo A et al (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749-2754
15. Cooney MM, van Heeckeren W, Bhakta S et al (2006) Drug insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery. Nat Clin Pract Oncol 3:682-692
16. Tozer GM, Kanthou C, Lewis G et al (2008) Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol 81 (Spec No 1):S12-S20
17. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423-435
18. Hinnen P, Eskens FA (2007) Vascular disrupting agents in clinical development. Br J Cancer 96:1159-1165
19. Soria JC, Sessa C, Perotti A et al (2008) A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors. AACR Meeting Abstracts; 2008: LB-302, Apr